Starting with use nivolumab (PD-L1 all corner, second line therapy, CheckMate-017, CheckMate-057 98), pembrolizumab (PD-L1 tumor proportion score ≥1%, second and further lines, KEYNOTE-010 99) and atezolizumab (PD-L1 all corner, second and further lines, OAK 100) after first line therapy with breakthrough results in increasing 5-year OS 101, there are currently a large number of immune-oncological first line treatment opportunities for both squamosus and not-squamosus mNSCLC. The gene discussed is CD274; the disease is neoplasm.